These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 34215909

  • 1. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa.
    Seefried L, Rak D, Petryk A, Genest F.
    Osteoporos Int; 2021 Dec; 32(12):2505-2513. PubMed ID: 34215909
    [Abstract] [Full Text] [Related]

  • 2. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
    Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP.
    Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866
    [Abstract] [Full Text] [Related]

  • 3. Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia.
    Stürznickel J, Schmidt FN, von Vopelius E, Delsmann MM, Schmidt C, Jandl NM, Oheim R, Barvencik F.
    Bone; 2021 Feb; 143():115794. PubMed ID: 33301963
    [Abstract] [Full Text] [Related]

  • 4. Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: A pooled post hoc analysis of asfotase alfa clinical trial data.
    Simmons JH, Rush ET, Petryk A, Zhou S, Martos-Moreno GÁ.
    Bone; 2020 Aug; 137():115413. PubMed ID: 32417537
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
    Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K.
    Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia.
    Seefried L, Kishnani PS, Moseley S, Denker AE, Watsky E, Whyte MP, Dahir KM.
    Bone; 2021 Jan; 142():115664. PubMed ID: 32987199
    [Abstract] [Full Text] [Related]

  • 8. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.
    Scott LJ.
    Drugs; 2016 Feb; 76(2):255-62. PubMed ID: 26744272
    [Abstract] [Full Text] [Related]

  • 9. Hypophosphatasia: From Diagnosis to Treatment.
    Simon S, Resch H, Klaushofer K, Roschger P, Zwerina J, Kocijan R.
    Curr Rheumatol Rep; 2018 Sep 10; 20(11):69. PubMed ID: 30203264
    [Abstract] [Full Text] [Related]

  • 10. Hypophosphatasia: presentation and response to asfotase alfa.
    Alsarraf F, Ali DS, Almonaei K, Al-Alwani H, Khan AA, Brandi ML.
    Osteoporos Int; 2024 Apr 10; 35(4):717-725. PubMed ID: 37993691
    [Abstract] [Full Text] [Related]

  • 11. Asfotase alfa therapy for children with hypophosphatasia.
    Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, Mack KE, Hamilton K, Kagan K, Fujita KP, Thompson DD, Moseley S, Odrljin T, Rockman-Greenberg C.
    JCI Insight; 2016 Jun 16; 1(9):e85971. PubMed ID: 27699270
    [Abstract] [Full Text] [Related]

  • 12. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa.
    Kishnani PS, Del Angel G, Zhou S, Rush ET.
    Mol Genet Metab; 2021 May 16; 133(1):113-121. PubMed ID: 33814268
    [Abstract] [Full Text] [Related]

  • 13. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.
    Hofmann C, Seefried L, Jakob F.
    Drugs Today (Barc); 2016 May 16; 52(5):271-85. PubMed ID: 27376160
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review.
    Shirinezhad A, Esmaeili S, Azarboo A, Tavakoli Y, Hoveidaei AH, Zareshahi N, Ghaseminejad-Raeini A.
    Bone; 2024 Nov 16; 188():117219. PubMed ID: 39089608
    [Abstract] [Full Text] [Related]

  • 15. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia.
    Dahir KM, Shannon A, Dunn D, Voegtli W, Dong Q, Hasan J, Pradhan R, Pelto R, Pan WJ.
    J Bone Miner Res; 2024 Sep 26; 39(10):1412-1423. PubMed ID: 39135540
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry.
    Kishnani PS, Martos-Moreno GÁ, Linglart A, Petryk A, Messali A, Fang S, Rockman-Greenberg C, Ozono K, Högler W, Seefried L, Dahir KM.
    Orphanet J Rare Dis; 2024 Mar 08; 19(1):109. PubMed ID: 38459585
    [Abstract] [Full Text] [Related]

  • 17. Asfotase Alfa in Perinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia: A Guide to Its Use in the USA.
    Scott LJ.
    BioDrugs; 2016 Feb 08; 30(1):41-8. PubMed ID: 26832358
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
    Bowden SA, Adler BH.
    Osteoporos Int; 2018 Feb 08; 29(2):511-515. PubMed ID: 29046930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.